Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab-IRDye800 for Optical Imaging in Ovarian Cancer Surgery
NCT07919509Phase 1Not yet recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Nov 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of panitumumab in ovarian cancer, sponsored by University of Alabama at Birmingham. Primary endpoint: Dose Limiting Toxicity at 15 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
panitumumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07919509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07919509.